Washington Feb 23: A new drug that works by blocking molecules responsible for cancer cell growth has been found to be effective for advanced breast cancer patients. The drug called palbociclib an investigational oral medication has been found to be well tolerated and extends progression-free survival (PFS) in newly diagnosed cancer. The palbociclib was recently approved by the US Food and Drug Administration (FDA) for metastatic breast cancer patients just beginning to undergo endocrine therapy. (Read: Mammography screening can reduce breast cancer deaths: Study) The FDA approval has expanded treatments options for many metastatic breast cancer patients but these new
